Metformin and Molecular Aging in Prediabetes

Plain-language summary

This study examined the effect of metformin treatment on markers of molecular aging (such as telomere length) in people with prediabetes. It included participants aged 30 to 60 with impaired glucose tolerance; those with type 1 or type 2 diabetes and pregnant or breastfeeding people were not included. It was a study without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

Diabetes Foundation, India

Intervention

Metformin treatment, Analyzed by qPCR for T/S ratio.

Start date

2/1/2023

Estimated completion

1/30/2025

Countries

India

Related genes

Locations

• New Delhi, India

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

Age: 30-60 years Both genders (male and female)

Diagnosis of pre-diabetes, defined as:

Impaired Fasting Glucose (IFG): Fasting plasma glucose 100-125 mg/dL AND/OR Impaired Glucose Tolerance (IGT): 2-hour plasma glucose 140-199 mg/dL after 75 g oral glucose tolerance test (OGTT)

IGT is mandatory (i.e., every participant must have IGT, even if IFG is also present)

Exclusion Criteria:

Type 1 diabetes mellitus Type 2 diabetes mellitus Pregnancy or lactation Hypoglycemia (blood glucose \<70 mg/dL) after medication Acute or chronic inflammatory diseases Immunological diseases (e.g., autoimmune diseases) History of organ transplantation Current or recent steroid therapy Uncontrolled arterial hypertension Known allergy or intolerance to metformin Major surgery or cardiovascular events (e.g., myocardial infarction, stroke) within the last 3 months